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ABSTRACT
Background. Polymorphic CYP2D6 is primarily responsible for
metabolic activation of tamoxifen to endoxifen. We previously
reportedthatbyincreasingthedailytamoxifendoseto40mg/day
in CYP2D6 intermediate metabolizer (IM), but not poor meta-
bolizer (PM), patients achieve endoxifen concentrations similar
to those of extensive metabolizer patients on 20 mg/day. We
expanded enrollment to assess the safety of CYP2D6 genotype-
guideddoseescalationand investigate concentrationdifferences
between races.
Methods. PMand IMbreast cancer patients currently receiving
tamoxifen at 20 mg/day were enrolled for genotype-guided
escalation to 40 mg/day. Endoxifen was measured at baseline
andafter4months.Quality-of-life datawere collectedusing the
Functional Assessment of Cancer Therapy-Breast (FACT-B) and
Breast Cancer Prevention Trial Menopausal Symptom Scale at
baseline and after 4 months.
Results. In 353 newly enrolled patients, genotype-guided dose
escalation eliminated baseline concentration differences in IM
(p 5 .08), but not PM (p 5 .009), patients. Endoxifen concen-
trationswere similar in black andwhite patients overall (p5 .63)
andwithin CYP2D6phenotypegroups (p. .05). In thequality-of-
life analysis of 480 patients, dose escalation did notmeaningfully
diminishqualityof life; in fact, improvementswereseen inseveral
measures including the FACT Breast Cancer subscale (p5 .004)
and limitations in range of motion (p, .0001) in IM patients.
Conclusion. Differences in endoxifen concentration during treat-
ment can be eliminated by doubling the tamoxifen dose in IM
patients,withoutanappreciableeffectonqualityof life.Validation
of the association between endoxifen concentration and efficacy
orprospectivedemonstrationof improvedefficacy isnecessary to
warrant clinical uptake of this personalized treatment strategy.
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Implications for Practice: This secondary analysis of a prospective CYP2D6 genotype-guided tamoxifen dose escalation study
confirms that escalation to 40 mg/day in patients with low-activity CYP2D6 phenotypes (poor or intermediate metabolizers)
increases endoxifen concentrations without any obvious increases in treatment-related toxicity. It remains unknown whether
endoxifen concentration is a useful predictor of tamoxifen efficacy, and thus, there is no current role in clinical practice forCYP2D6
genotype-guided tamoxifen dose adjustment. If future studies confirm the importance of endoxifen concentrations for tamoxifen
efficacy and report a target concentration, this study provides guidance for a dose-adjustment approach that could maximize
efficacy while maintaining patient quality of life.
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INTRODUCTION
Tamoxifen is a selective estrogen receptor modulator that is
highly effective in estrogen receptor-positive breast cancer
patients. Use of tamoxifen for 5 years decreases cancer re-
currence by approximately 50% in this setting [1], and possibly
more if used for 10 years [2, 3]. Tamoxifen is the only
approved endocrine agent for premenopausal women (with-
out ovarian suppression), is used in postmenopausal patients
who have a contraindication or intolerance to aromatase
inhibitors, and may be used in high-risk women for cancer
prevention.
Despite the proven efficacy of tamoxifen, some women
experience cancer recurrence during or after treatment. Thera-
peutic failuremay be caused by tumor resistance to antiestrogen
therapy[4,5]or inadequatebioactivationoftamoxifentoitsactive
metabolite, endoxifen [6, 7]. Some studies have reported that
patients with low endoxifen concentrations have inferior tamox-
ifen efficacy [8, 9], although this association has not been con-
sistently detected [10].
Activation of tamoxifen to endoxifen occurs through two
parallel pathways involving multiple cytochrome P450 (CYP)
enzymes [11]. Despite these complementary pathways, the
polymorphic CYP2D6 enzyme is responsible for a considerable
amount of endoxifen production. CYP2D6 metabolic activity
can be predicted from CYP2D6 genotype, enabling classifica-
tion of patients into poor (PM), intermediate (IM), extensive
(EM), or ultra-rapid (UM) metabolizer phenotypes [12]. Pa-
tientswith low-activity CYP2D6phenotypes have substantially
lower endoxifen steady-state concentrations [8, 13, 14]. It is
unclear whether patients with genotypes that confer low
CYP2D6 activity have inferior efficacy from tamoxifen treat-
ment [15–18], but if so, preemptive genotyping to guide
tamoxifen dose selection could be a viable strategy to improve
treatment effectiveness.
We have previously reported results of a prospective
clinical study of CYP2D6 genotype-guided tamoxifen dosing
that we conducted at the University of North Carolina and
several nearby community cancer clinics. Dose escalation in
patientswith intermediateCYP2D6activitysuccessfullyachieved
endoxifen concentrations similar to those seen in patients with
normal activity remaining on standard dosing [19]. Building on
the success of this pilot study, we expanded enrollment to 500
patients to achieve statistical power to assess whether dose
escalationhasanyadverseeffectontreatment-relatedtoxicityor
qualityof life,andto investigatewhethernonwhitepatientshave
similar endoxifen levels during tamoxifen treatment to further
refine individualized treatment strategies.
METHODS
Patients
A previous publication reported analysis of endoxifen con-
centrations before and after 4 months of genotype-guided
treatment in the original 120-patient cohort of University of
North Carolina Lineberger Comprehensive Cancer Center 0801
[19]. Briefly, women 18 years or older who were receiv-
ing tamoxifen 20 mg/day for at least 4 months were eligible
to enroll in a prospective CYP2D6 genotype-guided dose
escalation study. Patients were ineligible if they were taking
CYP2D6moderateorstronginhibitorsorhadEasternCooperative
Oncology Group performance status .2 or impaired kidney or
liver function.Afterenrollment,baselinedataandserumsamples
were collected to measure tamoxifen and metabolite concen-
trationsandpredictCYP2D6phenotype.Patients whowere EM
or UM continued on 20-mg/day treatment. Patientswith PM
or IM phenotypes had doses increased to 40mg/day. Patients
remained on this genotype-adjusted dose for 4 months, after
which additional data and sampleswere collected for analysis.
This study was approved by the institutional review boards of
the University of North Carolina at Chapel Hill and all other
participating institutions. All patients signed informedconsent
before participation. This report describes endoxifen concen-
trations in the380-patient expansion cohort and combines the
2 cohorts for a joint analysis of toxicity before and 4 months
after dose adjustment. A detailed description of the study
methods can be found in the original publication.
CYP2D6 Genotype and Phenotype
Whole blood collected at enrollment was used to isolate
genomic DNA for CYP2D6 genotyping using the AmpliChip
CYP450 test (Roche Diagnostics, Indianapolis, IN, https://
usdiagnostics.roche.com) in a Clinical Laboratory Improve-
ment Amendments-certified laboratory. The AmpliChip can
identify 20distinct alleles and7knownduplications,which can
then be combined to predict a CYP2D6 phenotype (PM, IM,
EM, or UM). A detailed description of the allelic coverage
and the translation system used can be found in our recent
publication describing the metabolic activity of individual
alleles anddiplotypes [13]. Becauseof the small numberofUM
patients, the similarity in tamoxifen dosing with EM patients,
and the marginal difference in endoxifen concentrations
between these groups, patients with UM and EM phenotypes
were combined for the toxicity analysis.
Tamoxifen and Endoxifen Concentrations
Blood samples were collected at enrollment, at which point all
patients had been on tamoxifen 20mg/day for at least 4months.
An additional sample was collected after 4 months of genotype-
guidedtreatment,withEM/UMpatientscontinuingon20mg/day
and PM or IM patients taking 40 mg/day. At each time point,
plasma concentrations of tamoxifen (Z isomer only), (Z)-4-
hydroxy-tamoxifen, N-desmethyl-tamoxifen (Z isomer only), and
(Z)-4-hydroxy-N-desmethyl-tamoxifen (endoxifen; 10% E, 90% Z)
weremeasuredusingahigh-performanceliquidchromatography/
tandemmassspectrometry(API3200)assaymethodaspreviously
described [19]. This analysis includes only endoxifen concen-
trations at baseline and 4 months for the 380 patients on the
expansionstudy,whichusedaslightlymodifiedendoxifenassay,as
previously described [13].
Quality-of-Life Data
Quality-of-life data were collected using the Functional Assess-
ment of Cancer Therapy-Breast, including the Endocrine Sub-
scale (FACT-B [ES]),Version 3, and the Breast Cancer Prevention
Trial Menopausal Symptom Scale (BCPT-MSS) at the time of
consent and after 4 months of genotype-guided treatment.
These validated scales collect patient-reported toxicity relevant
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to breast cancer endocrine therapy [20, 21]. The FACT-B [ES]
is subdivided into several subscales (physical, social/family,
emotional, functional, relationship with doctor, and addi-
tional concerns) and asks patients to rate how true a
statement has been for the past 7 days on a scale from 0 (not
at all) to 4 (very much). The BCPT-MSS asks how much
a patient was bothered on a scale of 0 (not at all) to
4 (extremely) in the past 4 weeks.
Statistical Analysis
Two separate analyses were conducted and reported in this
article. The first is the comparison of endoxifen concentrations
at baseline and after 4 months of genotype-guided treatment
between CYP2D6 phenotype groups and at baseline between
blackandwhitepatients.Endoxifenconcentrationwascompared
between groups using analysis of variance and two-group t tests.
All analyses of endoxifen concentrations were conducted in the
expansion cohort only, as the analysis in the original cohort has
been previously published [19].
The second analysis is a comparison of toxicity at baseline
and the change in quality of life from baseline to 4 months.
FACTwas scored as recommended, yielding scores for FACT-B
total, FACT-B trial outcome index, FACT-Endocrine subscale
total, and several subscales (physical, social/family, emotional,
functional, breast cancer, endocrine symptom). Additionally,
each individual toxicity item was analyzed separately. For all
FACT summary scores, higher scores indicate better quality of
life; however, for individual items on the endocrine symptom
subscale, higher scores indicate worse symptoms. BCPT-MSS
was also scored as recommended, by averaging across the
individual items, each subscale (hot flashes, nausea, bladder
control, vaginal problems, musculoskeletal, cognitive prob-
lems, weight problems, arm problems), and each individual
toxicity item.ForBCPT-MSS,all itemsrange from0(notatall) to
4 (extremely); thus, higher scores on both summary and
individual items indicate worse symptoms. All individual and
combined toxicity scores were compared across CYP2D6
phenotypes (PM, IM, and EM/UM) at baseline using linear
regression models, assuming an additive genetic effect. The
change inmean toxicity frombaseline to 4monthswithin each
phenotype group was evaluated using paired t tests. A
standard significance threshold of p , .05 was used for all
analyses, including the many hypothesis-generating quality-
of-life comparisons. Analyses were conducted using SAS
statistical software, version 9.3 (SAS Institute, Cary, NC,
http://www.sas.com).
RESULTS
Patient Characteristics by Genotype
A total of 500 patients were enrolled on the prospective
CYP2D6 genotype-guided tamoxifen clinical study. After ex-
cluding patients who were ineligible or had missing genotype
data, 480 were evaluable in the toxicity analysis. Only patients
enrolled on the expansion cohort are included in the comparison
of endoxifen concentration at baseline and after 4months of
genotype-guided treatment, because the original 120patients
havepreviouslybeenpublished[19].Aftereliminationofpatients
who were ineligible or had missing data, 353 patients were
evaluable in this follow-upanalysis, ofwhom344 self-reported
their race as white or black and were included in the race
analysis (supplementalonlineFig.1).Demographicdatafor the
480 patients evaluable in the toxicity analysis, including age,
race, menopausal status, duration of tamoxifen treatment
before enrollment, prior chemotherapy use, and tamoxifen
indication, can be found in Table 1.
Endoxifen at Baseline and 4 Months
All patients on this study were taking 20 mg/day of tamoxifen
at study entry. Steady-state endoxifen concentrations were
significantly higher in patients with EM/UM genotypes (mean
concentration10.00ng/mL) than in thosewith IM(7.10ng/mL,
p, .001) or PM (3.42 ng/mL, p, .001) genotypes (Table 2).
After 4 months of CYP2D6 genotype-dosed therapy, in which
PM and IM patients received double the dose, although a
significant difference in endoxifen concentration remained
(p 5 .01), it was markedly attenuated and was actually
eliminated in IMpatients. Significantdifferences still existed,
however, in IM patients, in whom endoxifen concentrations
had risen by48% to10.74 ng/mL,whichwas no longerdifferent
from, and was in fact nominally greater than, the endoxifen
concentrations in EM/UM patients (9.30 ng/mL, p 5 .08).
Endoxifen concentrations in genotype-dosed PM patients also
rose by approximately 61% but remained significantly lower
than in EM patients (5.52 ng/mL, p5 .009) or genotype-dosed
IMpatients(Table2,Fig.1).Theendoxifenconcentrationestimates
or statistical comparisons were not meaningfully altered by
excluding the 51 patients who had baseline endoxifen concen-
tration data but did not have 4-month concentrations (data not
shown).
A total of 344 self-describedwhite (n5 292) or black (n5 52)
patients were evaluable in the baseline comparison of endoxifen
concentration by race. At baseline, the mean endoxifen concen-
tration was similar in white and black patients (7.90 ng/mL vs.
7.51 ng/mL, p 5 .63). As expected, there were no statistically
significant differences in endoxifen concentration at baseline
in the CYP2D6 UM, EM, IM, or PM phenotype groups when
comparingwhite and black patients (all p. .05) (supplemental
online Table 1; Fig. 2).
Quality of Life at Baseline
In the 480 patients evaluable, there was no identifiable trend
in baseline toxicity across CYP2D6 phenotype groups for any
of the combined FACT or BCPT-MSS scales or subscales.
Patients reported decent overall quality of life (FACT-B scores
ranging from 116 to 119, out of 144) and relatively minor
decreases in quality of life as a result of their endocrine
therapy (FACT [ES] scores ranging from59 to 60, out of 72). As
metabolizer phenotype increased, there were significant
increases in several toxicities on the FACT scale, including
breast tenderness (p5 .016), vaginal dryness (p5 .050), and
vomiting (p5 .010),whereas therewas a significantdecrease
in vaginal bleeding (p5 .048) (Table 3). No differences were
identified by the BCPT-MSS, including lack of significance for
vaginal dryness (p 5 .25) and vomiting (p 5 .60), whereas
breast tenderness and vaginal bleeding are not assessed
by this scale. Comparisons across CYP2D6 phenotype for all
subscales and individual toxicities from both scales are
reported in supplemental online Table 2.
www.TheOncologist.com ©AlphaMed Press 2016
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Change in Quality of Life From Baseline to 4 Months
Increasing the dose from 20 to 40 mg/day did not cause a
concurrent increase in toxicity or decrease in patient quality of
life in PM and IM groups based on comparisons of the overall
scales or subscales (Table 4). However, therewere increases in
individual toxicity items for individual phenotype groups
(Table 5).The PMgroup reported an increase in distractedness
on the BCPT-MSS (D 5 0.42, 95% confidence interval [CI]
0.17–0.66, p5 .002), although the EM group also reported an
increase despite no dose change (D5 0.16, 95% CI 0.04–0.28,
p 5 .011). The IM group reported an increase in vaginal
discharge on FACT (D5 0.12, 95%CI 0.01–0.22, p5 .029) that
was not seen in either the PM or EM groups.
There were also improvements seen in individual toxicities
or quality-of-life measures within phenotype groups (Table 5).
The PM group experienced less pain with intercourse (FACT:
p5 .004, BCPT-MSS: p5 .002) and fewer mood swings (FACT:
p5 .031) and vaginal problems (BCPT-MSS: p5 .020). The IM
group reported decreased irritability (FACT: p 5 .015), de-
creased limitation in range ofmotion in the arm on the surgery
side (p, .0001), improvement on theBCPT armproblems scale
(p5 .001), andoverall improvement on the FACTTrialOutcome
Index (D5 0.85, 95%CI 0.08–1.63, p5 .031) andBreast Cancer
Subscale (D5 0.67, 95% CI 0.24–1.09, p5 .002). Finally, there
were decreases in reports of several toxicities in EM/UM
patients who remained on 20 mg/day, including decreased
BCPT-MSS hot flash summary score (D520.14, 95% CI20.26
to 20.02, p 5 .027) and decreases in night sweats on both
scales (FACT: p 5 .018, BCPT-MSS: p 5 .007). Changes for
every subscale and individual toxicity within each phenotype
group can be found in supplemental online Tables 3 and 4,
respectively.
DISCUSSION
ThisCYP2D6 genotype-guided tamoxifendosing studyallowed
us to assess any potential associations between CYP2D6
Table 1. Demographic data for all 480 subjects evaluable in toxicity analysis
Characteristic EM/UM IM PM
n 161 290 29
Age, yr
Median 51 52 48
Range 30–95 25–88 37–79
Self-reported race
White 140 (36) 225 (58) 25 (6)
Black 13 (18) 57 (77) 4 (5)
Other/unknown 8 (50) 8 (50) 0 (0)
Menopausal status
Pre-/perimenopause 70 (31) 141 (63) 13 (6)
Postmenopause 91 (36) 149 (58) 16 (6)
Duration of tamoxifen treatment before enrollment, yr
Median 0.88 0.95 1.02
Range 0.31-9.69 0.28-15.86 0.31-3.31
Prior chemotherapy
Yes 92 (35) 148 (57) 21 (8)
No 69 (32) 142 (65) 8 (4)
Tamoxifen indication
Invasive disease 144 (35) 236 (58) 27 (7)
Ductal carcinoma in situ 17 (26) 47 (71) 2 (3)
Other 0 6 (100) 0
Data are presented as n (%) unless noted otherwise.
Abbreviations: EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra-rapid metabolizer.
Table 2. Endoxifen concentrations at baseline (n5 353) and 4 months (n5 302) by CYP2D6 phenotype
Phenotype
Baseline endoxifen (20 mg/day), ng/mL 4-Month endoxifen (IM/PM 40 mg/day), ng/mL
n Mean (SD) p value vs. EMa n Mean (SD) p value vs. EMa
UM 5 8.40 (4.59) .56 4 15.35 (5.48) .02
EM 119 10.00 (6.00) 106 9.30 (5.03)
IM 212 7.10 (4.77) ,.001 179 10.74 (7.36) .08
PM 17 3.42 (2.75) ,.001 13 5.52 (2.57) .009
aBased on two-group t test.
Abbreviations: EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM: ultra-rapid metabolizer.
©AlphaMed Press 2016
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phenotype and (a) active endoxifen concentrations and (b)
toxicity when all patients were treated at the standard 20-mg/
day dose and when patients with low-activity phenotype were
escalated to40mg/day. In thisexpansionstudy,wevalidatedour
initial finding that increasing doses for IM patients normalizes
their endoxifen concentration with that of EM/UM patients
treated with standard doses, whereas endoxifen concentration
remains significantly lower inPMpatientsafterescalation.Other
similarstudies that increaseddoses inpatientsbasedonbaseline
endoxifen or CYP2D6 genotype have reported similar findings
[22, 23]. Our relatively large study enabled detailed assessment
of the consequences of dose escalation on treatment-related
toxicity andoverall quality of life.Wedidnotdetect any clinically
meaningful increases in treatment-related toxicity or decreases
in quality of life from tamoxifen dose escalation and could not
replicate prior reports of associations between CYP2D6 pheno-
type and toxicity. Therefore, our prospective study confirms the
clinical feasibility of genotype-directed tamoxifen treatment
to safely eliminate well-established differences in endoxifen
concentration in IM patients, which represents the majority
of women receiving tamoxifen.
CYP2D6 phenotype is a strong predictor of endoxifen
concentration; however, it is still unclearwhether endoxifen
concentration is associated with treatment efficacy [14].
Two studies have reported that patients below a threshold
endoxifen concentration (,5.9 ng/mL) have increased risk
of recurrence [8, 9]. This threshold is below the mean
endoxifen concentration in IM patients receiving standard
20-mg/day dosing (7.10 ng/mL) but above that of PM
patients after dose escalation to 40 mg/day (5.52 ng/mL) in
our study. If recurrence risk increases below this endoxifen
threshold, our data do not support the clinical utility of
increasing doses in IM or PM patients to 40 mg/day.
Alternatively, our study defined the endoxifen concentra-
tion of EM patients receiving standard dosing as the
“target.” In that case, our data support dose escalation in
IM patients to 40 mg/day, which our data suggests does
not increase toxicity or decrease quality of life. Based on our
results,PMpatientswould requireevenfurtherdoseescalation,
thesafetyofwhich isunknown.Wearenotawareofanydirect
evidence that the use of higher tamoxifen doses for the
general population improves treatment efficacy or enhances
toxicity. SomeEuropean countries use 30 or 40mg/day as the
standard of care. The Early Breast Cancer Trialists’ Collabo-
rative Groupmeta-analysis reported a higher recurrence risk
reduction with higher daily doses (p5 .02 for trend between
relative risks for 20, 30, and 40 mg/day), but not for breast
cancer mortality [24]. Lack of detectable benefit in the
general population does not preclude the possibility that
there is a subset of patients who would benefit from dose
escalation, for instance those with low endoxifen con-
centration during treatment. However, at this time, we do
not recommend any dose escalation approach, as the
connection between endoxifen concentration and efficacy,
or the effect on efficacy of genotype-directed dose es-
calation, has not been conclusively established [10]. Clinical
Figure 1. Endoxifen concentrations at baseline and 4 months by
CYP2D6 phenotype group. At baseline, with all patients receiving
20 mg/day of tamoxifen, there were significant differences in
endoxifen concentrations in EMpatients comparedwith IMorPM
patients (p, .001).After4monthsofdoseescalationto40mg/day
in the IM and PM patients, only the IM patients had endoxifen
concentrations similar to EMpatients (p5 .08), whereas the PM
patients continued to have lower endoxifen concentrations
(p5 .01), recapitulating the findings reported in the analysis of
the first 120 patients enrolled on this trial [18].
Abbreviations: EM, extensive metabolizer; IM, intermediate
metabolizer; PM, poor metabolizer; UM, ultra-rapid metabolizer.
Figure 2. Comparison of baseline endoxifen concentration in
white and black patients combined and stratified by CYP2D6
phenotype.White and black patients had similarmedian endoxifen
concentrations at baseline compared overall or within CYP2D6
phenotype groups (all p. .05).
Abbreviations: B, black; EM, extensive metabolizer; IM,
intermediate metabolizer; PM, poor metabolizer; UM, ultra-rapid
metabolizer; W, white.
www.TheOncologist.com ©AlphaMed Press 2016
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trials of endoxifen currently under way (Alliance A011203;
NCT02311933) could provide answers to someof these critical
questions.
The link between endoxifen, tamoxifen, or any other
metabolite concentration and toxicity is even less well
established. Previous publications have reported that CYP2D6
phenotype may be a predictor of toxicity [25], particularly hot
flashes [26, 27], but this has not been consistently found [28,
29]. Inourdataset,therewasnosignificantdifference inoverall
toxicity or hot flashes across CYP2D6 phenotype groups all
treatedat standarddoses.AsCYP2D6activity increased, breast
tenderness, vaginal dryness, and vomiting increased on the
FACT scale; however, these findings could not be repli-
cated in the BCPT-MSS data and have not been previously
reported to our knowledge. Our findings do not support
a robust link between CYP2D6 phenotype and toxicity
during treatment, suggesting that endoxifen concentration
is unlikely to be predictive of treatment-related toxicity or
vice versa. This again supports the clinical feasibility of dose
escalation in patients achieving suboptimal endoxifen
concentrations.
Similar to results previously reported in a study of 90
patients receiving genotype-guided tamoxifen dose escala-
tion [22], we did not detect ameaningful increase in toxicity
from dose escalation.These results are contrary to our prior
report of a significant increase in “severe toxicity” in IM
patients after dose escalation [30].That preliminary analysis
of this dataset dichotomized patients bywhether they rated
any toxicity 3 or 4 on the BCPT-MSS scale and compared the
proportion at baseline and after 4 months of treatment. A
small but statistically significant increase was reported by
IM patients, providing the basis for the hypotheses tested
formally in this analysis. Using the recommended scoring
approaches for these validated quality- of-life assessments,
we detected minor increases in distractedness and vaginal
discharge in PMand IMpatients, respectively. No composite
toxicity scale increased in either group, nor did any single
toxicity increase in both PM and IM groups. Many compar-
isons were conducted without proper statistical adjust-
ment, and these two nominal increases are likely because of
chance, not actual consequences of dose escalation. Further-
more, the number of toxicities that increased in PM and IM
patientswasexceededbythenumber thatdecreased, including
significant improvements in the FACT breast cancer subscale
and trial outcome index in IM patients.These improvements in
quality of life could be partially attributable to decreased
adherence,particularly inpatientswithtoxicity [31],ormaybea
consequenceof remainingontreatment foranextendedperiod
of time. It is possible that over time patients learn to prevent,
manage, or accept side effects associated with tamoxifen
treatment; however, there was no association between time
on tamoxifen treatment before enrollment and any of the
composite toxicity measures at baseline (data not shown).
Nevertheless, this explanation is partially supported by the
preponderance of decreased toxicity (improved quality of life)
reported by the EM/UM patients, who remained on standard
Table 3. Statistically significant differences in toxicity across phenotype groups at baseline
FACT-B symptom Maximum score EM/UMmean IMmean PMmean p valuea
Vaginal bleeding 4 0.09 0.11 0.34 .048
Vaginal dryness 4 1.06 0.85 0.76 .050
Vomiting 4 0.03 0.00 0.00 .010
Breast tenderness 4 0.74 0.58 0.31 .016
Higher scores indicate worse symptoms (0–4 scale).
aLinear regression assuming an additive genetic effect.
Abbreviations: EM, extensive metabolizer; FACT-B, Functional Assessment of Cancer Therapy-Breast; IM, intermediate metabolizer; PM, poor
metabolizer; UM: ultra-rapid metabolizer.
Table 4. Statistically significant changes in overall toxicity and toxicity subscales from baseline to 4 months (n5 421)
Test
EM/UM IM PM
Change 95% CI p valuea Change 95% CI p valuea Change 95% CI p valuea
FACT, breast cancer
subscale
0.09 20.50 to 0.67 0.77 0.67 0.24 to 1.09 0.002 20.24 21.74 to 1.25 0.74
FACT-B trial outcome
index
20.17 21.34 to 1.00 0.77 0.85 0.08 to 1.63 0.031 21.93 25.31 to 1.46 0.25
BCPT, hot flashes
summary score
20.14 20.26 to20.02 0.027 20.01 20.12 to 0.11 0.89 20.04 20.51 to 0.43 0.86
BCPT, vaginal problems
summary score
0.00 20.14 to 0.13 0.96 0.08 20.02 to 0.19 0.12 20.33 20.61 to20.06 0.020
BCPT, arm problems
summary score
20.02 20.12 to 0.07 0.65 -0.10 20.16 to20.04 0.001 20.06 20.22 to 0.09 0.42
Higher scores on FACT summary scales indicate better quality of life; higher scores on BCPT indicate worse symptoms. Bold text indicates statistical
significance (p, .05).
aBased on paired t test.
Abbreviations: BCPT, Breast Cancer Prevention Trial; EM, extensive metabolizer; FACT-B, Functional Assessment of Cancer Therapy-Breast; IM,
intermediate metabolizer; PM, poor metabolizer; UM: ultra-rapid metabolizer.
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dosingand serve as a pseudonegative control for this analysis. A
moredirect comparison could havebeenconducted if PMor IM
patients were randomized to dose escalation (40 mg/day) or
continued standard care (20 mg/day); however, given the
negative findings, it is unlikely that this would have detected
any meaningful changes in quality of life in the dose-escalated
patients.
In a secondary analysis of baseline endoxifen concentra-
tion, we did not detect an overall difference in self-reported
white andblack patients or a difference between raceswithin
CYP2D6 phenotype groups. Our understanding of CYP2D6
genetic variation seems to be sufficient to accurately predict
CYP2D6 phenotype from genotype information forwhite and
black patients. This is not the case with all pharmacogenetic
associations, as evidenced by the inferior performance of
genetically guided warfarin dosing strategies in African-
American patients [32], which has been attributed to racial
differences in the effect of clinical and genetic factors [33].
Interestingly, greater endoxifen concentrations have been
reported for Hispanic patients in comparison with non-
Hispanic white patients [34]. This could be partially attribut-
able to the lower frequency of CYP2D6 low-activity alleles
found in theHispanic cohort; however,within theCYP2D6EM
group, Hispanic patients had greater endoxifen concentra-
tions. This suggests that there could be additional genetic
variation within Hispanic patients that is not currently appreci-
ated, or perhaps there could be other nongenetic differences
that explain this finding. Unfortunately, we did not have a
sufficientnumberofHispanicpatientsto includethisgroupinany
analyses. Ongoing analyses of this robust dataset will identify
additional clinical and genetic factors, such as concomitant
treatment with weak CYP2D6 inhibitors, age, weight, or
season of sample collection, that could contribute to
the residual variability in endoxifen concentrations after
accounting for CYP2D6 genotype [35].
Several additional limitations of this analysis warrant
discussion. This study was not powered, designed, or in-
tended to collect any data on treatment efficacy; therefore,
the clinical utility of CYP2D6 genotype-guided tamoxi-
fen treatment cannot be evaluated. Relatedly, the quality-
of-life data were collected for only 6 months, whereas
treatment-related toxicity, particularly severe toxicities such
as thromboembolism, can take years to develop. Second, the
present analysis did not specifically analyze the relationship
between endoxifen concentration, or concentrations of any
other metabolite, and treatment toxicity. This analysis may
be conducted in the future but is beyond the scope of the
current article. Finally, there is likely some inherent bias
in our estimates of toxicity at baseline, given that only
patients who are not experiencing unacceptable toxicity would
continueon treatment longenough forenrollment toour study.
Adherence with tamoxifen therapy is known to be suboptimal,
and this may in fact be more pronounced in patients with high
CYP2D6activity [36], biasingour baseline comparisonof toxicity
across phenotypes. This limitation could be circumvented by
enrolling patients at treatment initiation, as opposed to
enrolling patients currently on treatment.
CONCLUSION
This prospective study verified that dose escalation in pa-
tients with low-activity CYP2D6 phenotypes increases
endoxifen concentrations without any evidence of enhanced
short-term treatment-related toxicity or deterioration in
patient quality of life. Decisions regarding which patients
should have doses increased, and by how much, require
validation that endoxifen concentration is associated with
treatment efficacy and identification of an optimal endoxifen
concentration target, or prospective demonstration that
genotype-guided tamoxifen dose escalation improves treat-
ment outcomes.
Table 5. Statistically significant changes in individual toxicities on the FACT-B and/or BCPT-MSS from baseline to 4months (n5 421)
Toxicity
EM/UM IM PM
FACT-B BCPT-MSS FACT-B BCPT-MSS FACT-B BCPT-MSS
Change p valuea Change p valuea Change p valuea Change p valuea Change p valuea Change p valuea
Night sweats 20.18 .018 20.20 .007 20.04 .58 0.00 .95 0.23 .45 0.22 .41
Vaginal discharge 20.09 .15 — — 0.12 .029 — — 0.00 1.00 — —
Pain/discomfort
with intercourse
0.02 .73 0.00 1.00 0.08 .09 0.08 .16 20.55 .004 20.48 .002
Mood swings 0.00 1.00 — — 20.10 .10 — — 20.30 .031 — —
Irritable 20.01 .83 20.13 .015 — — 20.13 .33 — —
Difficulty with
bladder control
when laugh/cry
— — 0.08 .16 — — 0.04 .43 — — 0.42 .038
Easily distracted — — 0.16 .011 — — 20.02 .69 — — 0.42 .002
Decreased range
of motion in arm
on surgery side
— — 20.02 .79 — — 20.19 <.0001 — — 20.17 .33
Average of score (0–4) at 4 months minus baseline for all patients in phenotype group. p value based on paired t test
For all items in this table, higher scores indicate worse symptoms. Bold text indicates statistical significance (p, .05).
aBased on paired t test.
Abbreviations:—, toxicity not collected on that scale; BCPT, Breast Cancer Prevention Trial; EM, extensive metabolizer; FACT-B, Functional
Assessment of Cancer Therapy-Breast; IM, intermediate metabolizer; MSS, Menopausal Symptom Scale; PM, poor metabolizer; UM, ultra-rapid
metabolizer.
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For Further Reading:
OlegGladkov,VladimirMoiseyenko, IgorN. Bondarenko et al. A Phase III Study of BalugrastimVersus Pegfilgrastim in Breast
Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. The Oncologist 2016;21:7–15.
Implications for Practice:
This paper provides efficacy and safety data for a new, once-per-cycle granulocyte colony-stimulating factor, balugrastim, for the
prevention of chemotherapy-induced neutropenia in patients with breast cancer receivingmyelosuppressive chemotherapy. In
this phase III trial, balugrastim was shown to be not inferior to pegfilgrastim in the duration of severe neutropenia in cycle 1 of
doxorubicin/docetaxel chemotherapy, and the safetyprofilesof the twoagentswere similar.Once-per-cyclebalugrastim is a safe
and effective alternative to pegfilgrastim for hematopoietic support in patients with breast cancer receiving myelosuppressive
chemotherapy associated with a greater than 20% risk of developing febrile neutropenia.
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